India produces over 60,000 generic drugs, highlights MoS Bhagwant Khuba

India‘s pharmaceuticals industry is the third largest by volume and the 13th largest by value in the world producing more than 60,000 generic drugs across 60 therapeutic categories, stated Minister of State (MoS) for Chemicals and Fertilizers, Bhagwant Khuba.

The statement from the minister came as a written reply on questions relating to the consumption of generic drugs in the last five years.

The reply also included the annual turnover of Indian pharmaceutical sector during the last five years. The turnover for FY22 stood at Rs 3,44,125 crore.

On being asked about government’s steps to enhance production of generic, affordable drugs, the MoS mentioned the two Production Linked Incentive (PLI) schemes that were launched to promote domestic manufacturing of key pharmaceutical ingredients and generic medicines.

The two PLIs include PLI scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs)/ Active Pharmaceutical Ingredients (APIs) with an outlay of Rs 6,940 crores and PLI scheme for Pharmaceuticals with an outlay of Rs 15,000 crore.

“Further, in order to provide quality generic medicines at affordable prices to all citizens, especially the poor and the deprived ones, Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) has been launched,” the minister stated in his reply to the question relating to government’s steps for providing affordable and quality medicines to the general public.

The government had announced the PLI scheme in 2021 for as many as 14 sectors, such as telecommunication, white goods, textiles and pharma with an outlay of Rs 1.97 lakh crore.

Of the 14 sectors, the scheme is fast picking in eight sectors – large-scale electronics, telecom, pharmaceuticals, food processing, white goods, and auto and auto components.

Related Posts

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

New Delhi: In a major crackdown on the sale of expired and substandard products, the Central Range team of Delhi Police Crime Branch has arrested one person and seized nearly…

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

Washington:  On March 18, 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance titled General Considerations for the Use of New Approach Methodologies in Drug Development. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

IPC releases draft NFI-2026 to promote rational use of medicines

IPC releases draft NFI-2026 to promote rational use of medicines

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

US market to dent India pharma earnings even as domestic growth remains firm

US market to dent India pharma earnings even as domestic growth remains firm

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg